Cboe Global Markets, Inc. (BATS:CBOE) vs. BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN …

Checking in on some valuation rankings, Cboe Global Markets, Inc. (BATS:CBOE) has a Value Composite score of 62. Developed by James …

Checking in on some valuation rankings, Cboe Global Markets, Inc. (BATS:CBOE) has a Value Composite score of 62. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 55.

Volatility comes with the territory when trading stocks. Individual stock prices can fluctuate dramatically, and returns can be largely varied. Because no stock is guaranteed to produce returns, there is a possibility that any stock could potentially lose value. Even though stock prices can shift from day to day, long-term investors are usually more concerned about price movements over an expanded period of time. Investors looking to minimize volatility risk may look to hold a larger number of diversified stocks in the portfolio. Even though market dips may have an impact on the entire portfolio, it is important to remember that it is just a normal part of investing in the stock market.

In taking a look at some other notable technicals, Cboe Global Markets, Inc. (BATS:CBOE)’s ROIC is 1.229466. The ROIC 5 year average is 1.703557 and the ROIC Quality ratio is 8.050145. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a firm is at turning capital into profits.

The Q.i. Value of Cboe Global Markets, Inc. (BATS:CBOE) is 43.00000. The Q.i. Value is a helpful tool in determining if a company is undervalued or not. The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the company is thought to be.

The FCF Yield 5yr Average is calculated by taking the five year average free cash flow of a company, and dividing it by the current enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The average FCF of a company is determined by looking at the cash generated by operations of the company. The Free Cash Flow Yield 5 Year Average of Cboe Global Markets, Inc. (BATS:CBOE) is 0.013330.

Shareholder Yield

We also note that Cboe Global Markets, Inc. (BATS:CBOE) has a Shareholder Yield of 0.019612 and a Shareholder Yield (Mebane Faber) of 0.03118. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

MF Rank

Cboe Global Markets, Inc. (BATS:CBOE) has a current MF Rank of 3729. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

PI

We can now take aquick look at some historical stock price index data. Cboe Global Markets, Inc. (BATS:CBOE) presently has a 10 month price index of 1.11092. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period.

A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 1.21022, the 24 month is 1.22197, and the 36 month is 1.78682. Narrowing in a bit closer, the 5 month price index is 1.27836, the 3 month is 1.14095, and the 1 month is currently 1.08701.

Volatility comes with the territory when trading stocks. Individual stock prices can fluctuate dramatically, and returns can be largely varied. Because no stock is guaranteed to produce returns, there is a possibility that any stock could potentially lose value. Even though stock prices can shift from day to day, long-term investors are usually more concerned about price movements over an expanded period of time. Investors looking to minimize volatility risk may look to hold a larger number of diversified stocks in the portfolio. Even though market dips may have an impact on the entire portfolio, it is important to remember that it is just a normal part of investing in the stock market.

The Value Composite One (VC1) is a method that investors use to determine a company’s value. The Value Composite score of BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) is 77. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) is 78.

Technicals



Volatility comes with the territory when trading stocks. Individual stock prices can fluctuate dramatically, and returns can be largely varied. Because no stock is guaranteed to produce returns, there is a possibility that any stock could potentially lose value. Even though stock prices can shift from day to day, long-term investors are usually more concerned about price movements over an expanded period of time. Investors looking to minimize volatility risk may look to hold a larger number of diversified stocks in the portfolio. Even though market dips may have an impact on the entire portfolio, it is important to remember that it is just a normal part of investing in the stock market.

In taking a look at some other notable technicals, BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN)’s ROIC is -0.068912. The ROIC 5 year average is -0.106575 and the ROIC Quality ratio is 0.129482. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a firm is at turning capital into profits.

We also note that BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) has a Shareholder Yield of -0.013344 and a Shareholder Yield (Mebane Faber) of 0.01576. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) has a current MF Rank of 12415. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

We can now take a quick look at some historical stock price index data. BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) presently has a 10 month price index of 0.79650. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 0.75495, the 24 month is 0.90434, and the 36 month is 0.78003. Narrowing in a bit closer, the 5 month price index is 0.85047, the 3 month is 0.88379, and the 1 month is currently 0.93561.

The C-Score is a system developed by James Montier that helps determine whether a company is involved in falsifying their financial statements. The C-Score is calculated by a variety of items, including a growing difference in net income verse cash flow, increasing days outstanding, growing days sales of inventory, increasing assets to sales, declines in depreciation, and high total asset growth. The C-Score of BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN) is -1.00000. The score ranges on a scale of -1 to 6. If the score is -1, then there is not enough information to determine the C-Score. If the number is at zero (0) then there is no evidence of fraudulent book cooking, whereas a number of 6 indicates a high likelihood of fraudulent activity. The C-Score assists investors in assessing the likelihood of a company cheating in the books.

Investors might be trying to figure out the best way to approach the stock market. After creating a plan that includes a list of stocks to purchase, investors may be looking to gauge the best time to enter the trade. With markets still cruising along at high altitudes, investors may be worried about buying at the top. Most individuals would probably agree that getting out before the market drops would be the best play. Obviously this is much easier said than done. If the warning signs were blatant, everyone would know exactly when to sell and when to re-buy. When the stock market has a big decline, the natural instinct is generally to sell in order to protect gains or eliminate further losses. Trying to time the market can have negative implications for investors who are not prepared to handle extremely volatile market conditions. Being prepared for any sudden change in the overall economy or stock market conditions may help the investor stay afloat for the long haul.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

QUALCOMM, Inc. (NASDAQ:QCOM) Shares Sold by Amica Retiree Medical Trust

Amica Retiree Medical Trust cut its stake in shares of QUALCOMM, Inc. (NASDAQ:QCOM) by 19.2% in the 2nd quarter, according to the company in its …

QUALCOMM logoAmica Retiree Medical Trust cut its stake in shares of QUALCOMM, Inc. (NASDAQ:QCOM) by 19.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,182 shares of the wireless technology company’s stock after selling 1,234 shares during the quarter. Amica Retiree Medical Trust’s holdings in QUALCOMM were worth $394,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of QCOM. Weaver Consulting Group acquired a new stake in QUALCOMM in the first quarter valued at $25,000. Farmers National Bank acquired a new stake in QUALCOMM in the first quarter valued at $26,000. Meridian Wealth Management LLC acquired a new stake in QUALCOMM in the first quarter valued at $26,000. Ibex Wealth Advisors acquired a new stake in QUALCOMM in the second quarter valued at $28,000. Finally, Mark Sheptoff Financial Planning LLC acquired a new stake in QUALCOMM in the first quarter valued at $29,000. 79.55% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have commented on QCOM shares. TheStreet raised QUALCOMM from a “c+” rating to a “b-” rating in a report on Thursday, August 1st. Stifel Nicolaus restated a “buy” rating and issued a $100.00 price target (up previously from $96.00) on shares of QUALCOMM in a research report on Thursday, May 2nd. Morgan Stanley set a $89.00 price target on QUALCOMM and gave the company a “buy” rating in a research report on Wednesday, August 21st. JPMorgan Chase & Co. raised their price target on QUALCOMM from $88.00 to $96.00 and gave the company a “positive” rating in a research report on Thursday, May 2nd. Finally, Rosenblatt Securities reiterated a “buy” rating and set a $84.00 price objective on shares of QUALCOMM in a research report on Thursday, May 2nd. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $79.69.

Shares of NASDAQ:QCOM opened at $74.35 on Thursday. The firm has a market cap of $89.38 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.03 and a beta of 1.62. QUALCOMM, Inc. has a 12-month low of $49.10 and a 12-month high of $90.34. The company has a current ratio of 1.77, a quick ratio of 1.61 and a debt-to-equity ratio of 2.46. The stock’s 50-day moving average price is $73.68 and its two-hundred day moving average price is $68.65.

QUALCOMM (NASDAQ:QCOM) last released its quarterly earnings data on Wednesday, July 31st. The wireless technology company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.02. The business had revenue of $4.89 billion for the quarter, compared to analyst estimates of $5.12 billion. QUALCOMM had a return on equity of 112.21% and a net margin of 13.41%. The company’s revenue was down 12.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.01 EPS. As a group, research analysts forecast that QUALCOMM, Inc. will post 2.84 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 26th. Stockholders of record on Thursday, September 12th will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 3.34%. The ex-dividend date is Wednesday, September 11th. QUALCOMM’s dividend payout ratio is currently 77.74%.

In other news, SVP Erin L. Polek sold 1,478 shares of QUALCOMM stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $70.36, for a total value of $103,992.08. Following the transaction, the senior vice president now directly owns 1,386 shares of the company’s stock, valued at approximately $97,518.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.11% of the company’s stock.

QUALCOMM Profile

QUALCOMM Incorporated designs, develops, manufactures, and markets digital communication products worldwide. It operates through three segments: Qualcomm CDMA Technologies (QCT); Qualcomm Technology Licensing (QTL); and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on code division multiple access (CDMA), orthogonal frequency division multiple access, and other technologies for use in wireless voice and data communications, networking, application processing, multimedia, and global positioning system products.

See Also: Beige Book

Institutional Ownership by Quarter for QUALCOMM (NASDAQ:QCOM)

Receive News & Ratings for QUALCOMM Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for QUALCOMM and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Hall Laurie J Trustee Lowers Position in QUALCOMM, Inc. (NASDAQ:QCOM)

Hall Laurie J Trustee lessened its holdings in shares of QUALCOMM, Inc. (NASDAQ:QCOM) by 3.9% in the 2nd quarter, according to its most recent …

QUALCOMM logoHall Laurie J Trustee lessened its holdings in shares of QUALCOMM, Inc. (NASDAQ:QCOM) by 3.9% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 5,676 shares of the wireless technology company’s stock after selling 229 shares during the period. Hall Laurie J Trustee’s holdings in QUALCOMM were worth $432,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Weaver Consulting Group acquired a new position in shares of QUALCOMM in the 1st quarter valued at $25,000. Ibex Wealth Advisors bought a new position in QUALCOMM during the 2nd quarter worth about $28,000. Hexavest Inc. bought a new position in QUALCOMM during the 2nd quarter worth about $33,000. Lenox Wealth Advisors LLC bought a new position in QUALCOMM during the 2nd quarter worth about $34,000. Finally, Meridian Wealth Management LLC bought a new position in QUALCOMM during the 1st quarter worth about $26,000. 79.55% of the stock is owned by institutional investors and hedge funds.

In other news, SVP Erin L. Polek sold 1,478 shares of the firm’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $70.36, for a total transaction of $103,992.08. Following the sale, the senior vice president now owns 1,386 shares in the company, valued at approximately $97,518.96. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.11% of the company’s stock.

A number of research firms have issued reports on QCOM. Deutsche Bank lowered their target price on QUALCOMM from $80.00 to $75.00 and set an “in-line” rating for the company in a report on Thursday, August 1st. Stifel Nicolaus restated a “buy” rating and issued a $100.00 price objective (up previously from $96.00) on shares of QUALCOMM in a report on Thursday, May 2nd. Cowen reiterated an “outperform” rating and set a $80.00 price target (down previously from $100.00) on shares of QUALCOMM in a report on Thursday, May 23rd. Citigroup lifted their price target on QUALCOMM from $55.00 to $85.00 and gave the stock a “neutral” rating in a report on Thursday, May 2nd. Finally, DZ Bank restated a “sell” rating on shares of QUALCOMM in a research report on Friday, August 2nd. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $79.69.

Shares of NASDAQ QCOM opened at $74.35 on Thursday. The company has a current ratio of 1.77, a quick ratio of 1.61 and a debt-to-equity ratio of 2.46. QUALCOMM, Inc. has a 1-year low of $49.10 and a 1-year high of $90.34. The firm has a market capitalization of $89.38 billion, a P/E ratio of 23.31, a P/E/G ratio of 2.03 and a beta of 1.62. The firm’s 50-day moving average price is $73.68 and its 200-day moving average price is $68.65.

QUALCOMM (NASDAQ:QCOM) last issued its quarterly earnings data on Wednesday, July 31st. The wireless technology company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.62 by $0.02. QUALCOMM had a net margin of 13.41% and a return on equity of 112.21%. The business had revenue of $4.89 billion during the quarter, compared to the consensus estimate of $5.12 billion. During the same period in the prior year, the firm posted $1.01 EPS. The firm’s quarterly revenue was down 12.7% compared to the same quarter last year. Equities research analysts forecast that QUALCOMM, Inc. will post 2.84 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 26th. Shareholders of record on Thursday, September 12th will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 3.34%. The ex-dividend date of this dividend is Wednesday, September 11th. QUALCOMM’s dividend payout ratio is presently 77.74%.

About QUALCOMM

QUALCOMM Incorporated designs, develops, manufactures, and markets digital communication products worldwide. It operates through three segments: Qualcomm CDMA Technologies (QCT); Qualcomm Technology Licensing (QTL); and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on code division multiple access (CDMA), orthogonal frequency division multiple access, and other technologies for use in wireless voice and data communications, networking, application processing, multimedia, and global positioning system products.

Read More: How is the Producer Price Index calculated?

Institutional Ownership by Quarter for QUALCOMM (NASDAQ:QCOM)

Receive News & Ratings for QUALCOMM Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for QUALCOMM and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

CME Group Inc (NASDAQ:CME) Shares Sold by AGF Investments Inc.

AGF Investments Inc. decreased its holdings in shares of CME Group Inc (NASDAQ:CME) by 21.1% in the 2nd quarter, according to the company in its …

CME Group logoAGF Investments Inc. decreased its holdings in shares of CME Group Inc (NASDAQ:CME) by 21.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,500 shares of the financial services provider’s stock after selling 400 shares during the period. AGF Investments Inc.’s holdings in CME Group were worth $291,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the business. Independent Advisor Alliance raised its holdings in CME Group by 5.9% during the first quarter. Independent Advisor Alliance now owns 1,947 shares of the financial services provider’s stock valued at $321,000 after acquiring an additional 108 shares during the period. Fox Run Management L.L.C. purchased a new position in CME Group in the second quarter worth about $571,000. Jackson Hole Capital Partners LLC grew its position in CME Group by 4.1% in the first quarter. Jackson Hole Capital Partners LLC now owns 1,986 shares of the financial services provider’s stock worth $327,000 after acquiring an additional 79 shares in the last quarter. KC Investment Advisors LLC grew its position in CME Group by 9.0% in the first quarter. KC Investment Advisors LLC now owns 2,898 shares of the financial services provider’s stock worth $477,000 after acquiring an additional 240 shares in the last quarter. Finally, United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund grew its position in CME Group by 609.0% in the first quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 122,785 shares of the financial services provider’s stock worth $20,208,000 after acquiring an additional 105,468 shares in the last quarter. 85.72% of the stock is owned by institutional investors.

Several research analysts recently commented on the company. Deutsche Bank lifted their price target on CME Group from $224.00 to $240.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. UBS Group lifted their price target on CME Group from $190.00 to $194.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 3rd. BidaskClub upgraded CME Group from a “hold” rating to a “buy” rating in a research report on Friday, August 9th. Zacks Investment Research lowered CME Group from a “hold” rating to a “sell” rating and set a $158.00 price target for the company. in a research report on Monday, May 27th. Finally, Wells Fargo & Co lifted their price target on CME Group from $176.00 to $200.00 and gave the stock a “market perform” rating in a research report on Wednesday, July 3rd. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the stock. CME Group has an average rating of “Hold” and an average target price of $194.00.

Shares of CME opened at $215.76 on Thursday. The company’s fifty day moving average price is $207.88 and its 200-day moving average price is $188.20. The firm has a market capitalization of $75.64 billion, a PE ratio of 31.64, a price-to-earnings-growth ratio of 4.70 and a beta of 0.23. CME Group Inc has a 1-year low of $161.05 and a 1-year high of $217.65. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.05 and a quick ratio of 1.05.

CME Group (NASDAQ:CME) last issued its quarterly earnings data on Wednesday, July 31st. The financial services provider reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.75 by $0.01. The business had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. CME Group had a net margin of 39.36% and a return on equity of 9.14%. The company’s revenue was up 20.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.74 earnings per share. As a group, research analysts anticipate that CME Group Inc will post 6.68 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 25th. Shareholders of record on Tuesday, September 10th will be given a $0.75 dividend. The ex-dividend date is Monday, September 9th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.39%. CME Group’s dividend payout ratio (DPR) is currently 43.99%.

In related news, CEO Terrence A. Duffy sold 35,000 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $200.15, for a total transaction of $7,005,250.00. Following the completion of the transaction, the chief executive officer now owns 79,057 shares in the company, valued at approximately $15,823,258.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Kevin Kometer sold 16,140 shares of the company’s stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $201.19, for a total transaction of $3,247,206.60. Following the transaction, the insider now owns 72,122 shares of the company’s stock, valued at approximately $14,510,225.18. The disclosure for this sale can be found here. In the last quarter, insiders sold 76,771 shares of company stock valued at $15,398,375. Insiders own 1.20% of the company’s stock.

CME Group Profile

CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals, as well as fixed income products.

See Also: Why is total return important?

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CME Group and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Value Composite Update on CME Group Inc. (NasdaqGS:CME) and CVS Health Corporation …

CME Group Inc. (NasdaqGS:CME) currently has a Value Composite score of 67. Similarly, the Value Composite Two (VC2) is calculated with the same …

CME Group Inc. (NasdaqGS:CME) currently has a Value Composite score of 67. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of CME Group Inc. (NasdaqGS:CME) is 71.

Volatility comes with the territory when trading stocks. Individual stock prices can fluctuate dramatically, and returns can be largely varied. Because no stock is guaranteed to produce returns, there is a possibility that any stock could potentially lose value. Even though stock prices can shift from day to day, long-term investors are usually more concerned about price movements over an expanded period of time. Investors looking to minimize volatility risk may look to hold a larger number of diversified stocks in the portfolio. Even though market dips may have an impact on the entire portfolio, it is important to remember that it is just a normal part of investing in the stock market.

In taking a look at some other notable technicals, CME Group Inc. (NasdaqGS:CME)’s ROIC is 0.627276. The ROIC 5 year average is 0.553416 and the ROIC Quality ratio is 12.236357. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a firm is at turning capital into profits.

The Q.i. Value of CME Group Inc. (NasdaqGS:CME) is 48.00000. The Q.i. Value is a helpful tool in determining if a company is undervalued or not. The Q.i. Value is calculated using the following ratios: EBITDA Yield, Earnings Yield, FCF Yield, and Liquidity. The lower the Q.i. value, the more undervalued the company is thought to be.

The FCF Yield 5yr Average is calculated by taking the five year average free cash flow of a company, and dividing it by the current enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The average FCF of a company is determined by looking at the cash generated by operations of the company. The Free Cash Flow Yield 5 Year Average of CME Group Inc. (NasdaqGS:CME) is 0.014498.

Shareholder Yield

We also note that CME Group Inc. (NasdaqGS:CME) has a Shareholder Yield of -0.032643 and a Shareholder Yield (Mebane Faber) of -0.04651. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

MF Rank

CME Group Inc. (NasdaqGS:CME) has a current MF Rank of 4882. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

PI

We can now take aquick look at some historical stock price index data. CME Group Inc. (NasdaqGS:CME) presently has a 10 month price index of 1.22733. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period.

A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 1.30230, the 24 month is 1.78910, and the 36 month is 2.16917. Narrowing in a bit closer, the 5 month price index is 1.33307, the 3 month is 1.15866, and the 1 month is currently 1.08305.

Volatility comes with the territory when trading stocks. Individual stock prices can fluctuate dramatically, and returns can be largely varied. Because no stock is guaranteed to produce returns, there is a possibility that any stock could potentially lose value. Even though stock prices can shift from day to day, long-term investors are usually more concerned about price movements over an expanded period of time. Investors looking to minimize volatility risk may look to hold a larger number of diversified stocks in the portfolio. Even though market dips may have an impact on the entire portfolio, it is important to remember that it is just a normal part of investing in the stock market.

Taking a look at valuation rankings for CVS Health Corporation (NYSE:CVS), we see that the stock has a Value Composite score of 20. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 35.

Technicals



Volatility comes with the territory when trading stocks. Individual stock prices can fluctuate dramatically, and returns can be largely varied. Because no stock is guaranteed to produce returns, there is a possibility that any stock could potentially lose value. Even though stock prices can shift from day to day, long-term investors are usually more concerned about price movements over an expanded period of time. Investors looking to minimize volatility risk may look to hold a larger number of diversified stocks in the portfolio. Even though market dips may have an impact on the entire portfolio, it is important to remember that it is just a normal part of investing in the stock market.

In taking a look at some other notable technicals, CVS Health Corporation (NYSE:CVS)’s ROIC is 0.191774. The ROIC 5 year average is 0.565074 and the ROIC Quality ratio is 17.327644. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a firm is at turning capital into profits.

We also note that CVS Health Corporation (NYSE:CVS) has a Shareholder Yield of -0.244905 and a Shareholder Yield (Mebane Faber) of -0.59285. The first value is calculated by adding the dividend yield to the percentage of repurchased shares. The second value adds in the net debt repaid yield to the calculation. Shareholder yield has the ability to show how much money the firm is giving back to shareholders via a few different avenues. Companies may issue new shares and buy back their own shares. This may occur at the same time. Investors may also use shareholder yield to gauge a baseline rate of return.

CVS Health Corporation (NYSE:CVS) has a current MF Rank of 4287. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are trading at an attractive price. The formula uses ROIC and earnings yield ratios to find quality, undervalued stocks. In general, companies with the lowest combined rank may be the higher quality picks.

We can now take a quick look at some historical stock price index data. CVS Health Corporation (NYSE:CVS) presently has a 10 month price index of 0.86036. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 0.81674, the 24 month is 0.83740, and the 36 month is 0.69956. Narrowing in a bit closer, the 5 month price index is 1.12800, the 3 month is 1.13264, and the 1 month is currently 1.05208.

The C-Score is a system developed by James Montier that helps determine whether a company is involved in falsifying their financial statements. The C-Score is calculated by a variety of items, including a growing difference in net income verse cash flow, increasing days outstanding, growing days sales of inventory, increasing assets to sales, declines in depreciation, and high total asset growth. The C-Score of CVS Health Corporation (NYSE:CVS) is 3.00000. The score ranges on a scale of -1 to 6. If the score is -1, then there is not enough information to determine the C-Score. If the number is at zero (0) then there is no evidence of fraudulent book cooking, whereas a number of 6 indicates a high likelihood of fraudulent activity. The C-Score assists investors in assessing the likelihood of a company cheating in the books.

Investors might be trying to figure out the best way to approach the stock market. After creating a plan that includes a list of stocks to purchase, investors may be looking to gauge the best time to enter the trade. With markets still cruising along at high altitudes, investors may be worried about buying at the top. Most individuals would probably agree that getting out before the market drops would be the best play. Obviously this is much easier said than done. If the warning signs were blatant, everyone would know exactly when to sell and when to re-buy. When the stock market has a big decline, the natural instinct is generally to sell in order to protect gains or eliminate further losses. Trying to time the market can have negative implications for investors who are not prepared to handle extremely volatile market conditions. Being prepared for any sudden change in the overall economy or stock market conditions may help the investor stay afloat for the long haul.

Related Posts:

  • No Related Posts